NovoCure Limited (NVCR)

14.19 +1.45 (+11.38%) 收市：04:00PM EDT

NovoCure Limited

No. 4 The Forum
Second Floor Grenville Street
Saint Helier JE2 4UF
Jersey
44 15 3475 6700
https://www.novocure.com

版塊: Healthcare
行業: Medical Devices
全職員工: 1,453

高階主管

名稱	頭銜	支付	行使價	出生年份
Mr. William F. Doyle	Executive Chairman	1.52M	無	1962
Mr. Asaf Danziger	CEO & Director	1.7M	無	1966
Ms. Ashley Cordova	Chief Financial Officer	933.39k	461.89k	1979
Mr. Wilhelmus C. M. Groenhuysen	Chief Operating Officer	1.01M	無	1958
Mr. Frank Leonard	Executive VP & President of Novocure Oncology	723.1k	457.08k	無
Prof. Yoram Palti M.D., Ph.D.	Founder & CTO	282.51k	無	1938
Dr. Moshe Giladi Ph.D.	Chief Science Officer	無	無	1970
Ms. Ingrid Goldberg	VP of Investor Relations	無	無	無
Mr. Barak Ben Arye	General Counsel	無	無	1977
Mr. Michael Puri	Chief Human Resources Officer	無	無	1969

截止 2022年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.

公司管治

截至 2024年5月1日 止，NovoCure Limited 的 ISS 管治質素評分為 2。 Pillar 分數正在審核中：1；董事會：4；股東權利：3；現金賠償：5。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。